United States Patent 9,974,790: A Comprehensive Analysis
Introduction
United States Patent 9,974,790, issued to Incyte Corporation, is a significant patent in the realm of pharmaceutical formulations, particularly for the treatment of skin disorders. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Invention Description
The patent 9,974,790 pertains to pharmaceutical formulations for topical skin application, specifically involving the compound (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof. This compound is known for its efficacy in treating various skin disorders, including atopic dermatitis and other inflammatory skin conditions[2].
Scope of the Patent
Claims
The patent includes multiple claims that define the scope of the invention. These claims cover:
- The specific chemical compound and its pharmaceutically acceptable salts.
- Topical formulations containing this compound, including creams, ointments, and gels.
- Methods of treating skin disorders by administering these formulations.
- Specific concentrations and dosing regimens for the treatment of atopic dermatitis and other skin conditions[2].
Key Components
- Chemical Compound: The patent centers around a specific Janus kinase (JAK) inhibitor, which is crucial for its therapeutic effects.
- Formulations: The patent describes various topical formulations that can be used to deliver the compound effectively.
- Therapeutic Uses: The primary focus is on treating skin disorders, with a particular emphasis on atopic dermatitis.
Patent Landscape
Related Patents
The patent 9,974,790 is part of a larger family of patents related to JAK inhibitors and their applications in treating various diseases. Other related patents include:
- Patent 11,510,923: This patent, also from Incyte Corporation, deals with ruxolitinib formulations for reducing itch in atopic dermatitis, highlighting the ongoing research in this area[2].
- Patent 8,415,362: This earlier patent covers pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as JAK inhibitors, showing the evolution of research in this field[2].
Competitors and Market
The patent landscape in the field of JAK inhibitors is highly competitive, with several major pharmaceutical companies involved:
- Incyte Corporation: As the assignee of this patent, Incyte is a key player in the development of JAK inhibitors for various therapeutic applications.
- Other Players: Companies like Pfizer, Eli Lilly, and Novartis also have significant presence in this market, each with their own portfolio of patents related to JAK inhibitors and other kinase inhibitors[3].
Expiration Dates and Patent Life
The patent 9,974,790 has a significant impact on the market until its expiration. The patent is set to expire on May 20, 2031, which gives Incyte Corporation exclusive rights to the invention for several more years[2].
Impact on Industry
Therapeutic Advancements
This patent contributes to the advancement of treatments for skin disorders, particularly atopic dermatitis, by providing effective topical formulations.
- Clinical Significance: The use of JAK inhibitors in topical formulations has shown promising results in reducing symptoms and improving quality of life for patients with atopic dermatitis.
Market Dominance
Incyte Corporation's control over this patent allows it to maintain a competitive edge in the market for treatments of skin disorders.
- Monopoly Period: Until the patent expires, Incyte can exclusively manufacture and market these formulations, which can lead to significant revenue and market dominance.
Regulatory Environment
USPTO Guidelines
The patent was granted under the guidelines set by the United States Patent and Trademark Office (USPTO). The USPTO's Revised Patent Subject Matter Eligibility Guidance ensures that such patents meet the criteria for novelty, non-obviousness, and utility[3].
Future Developments
Ongoing Research
The field of JAK inhibitors is continuously evolving, with ongoing research aimed at improving formulations and expanding therapeutic applications.
- New Formulations: Future patents may cover new formulations or dosing regimens that enhance the efficacy or reduce the side effects of these treatments.
Competitive Landscape
As the patent nears its expiration date, other companies may begin to develop generic or alternative versions of these formulations, potentially altering the competitive landscape.
Key Takeaways
- Specific Compound: The patent centers around a specific JAK inhibitor compound.
- Topical Formulations: It covers various topical formulations for treating skin disorders.
- Therapeutic Uses: Primarily focused on atopic dermatitis and other inflammatory skin conditions.
- Expiration Date: Set to expire on May 20, 2031.
- Market Impact: Significant for Incyte Corporation’s market dominance and therapeutic advancements.
FAQs
What is the main compound covered by this patent?
The main compound is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
What are the primary therapeutic uses of this patent?
The primary therapeutic uses are for treating skin disorders, particularly atopic dermatitis and other inflammatory skin conditions.
Who is the assignee of this patent?
The assignee of this patent is Incyte Corporation.
When does the patent expire?
The patent is set to expire on May 20, 2031.
How does this patent impact the market?
This patent gives Incyte Corporation exclusive rights to manufacture and market these formulations, allowing it to maintain a competitive edge in the market for treatments of skin disorders.
Cited Sources
- United States Patent and Trademark Office, "US10610530.pdf" - googleapis.com
- Drugs.com, "Generic Opzelura Availability" - drugs.com
- Mintz, "Is Your Blockchain Invention Patentable?" - mintz.com
- United States Patent and Trademark Office, "US11331320.pdf" - googleapis.com
- Unified Patents Portal, "US-20060020011-A1" - unifiedpatents.com
